Zhang, Xinyu
Hu, Ying
Aouizerat, Bradley E.
Peng, Gang
Marconi, Vincent C.
Corley, Michael J.
Hulgan, Todd
Bryant, Kendall J.
Zhao, Hongyu
Krystal, John H.
Justice, Amy C.
Xu, Ke
Funding for this research was provided by:
National Institute on Drug Abuse (R03 DA039745, R01 DA038632, R01DA047820, R01DA047063)
Article History
Received: 19 September 2018
Accepted: 26 November 2018
First Online: 13 December 2018
Ethics approval and consent to participate
: The study was approved by the committee of the Human Research Subject Protection at Yale University and the Institutional Research Board Committee of the Connecticut Veteran Healthcare System. All subjects provided written consents.
: The following are the competing interests of Dr. John H Krystal: (1) Consultant: note: The Individual Consultant Agreements listed below are less than $10,000 per year: AstraZeneca Pharmaceuticals; Biogen, Idec, MA; Biomedisyn Corporation; Bionomics, Limited (Australia); Concert Pharmaceuticals, Inc.; Heptares Therapeutics, Limited (UK); Janssen Research & Development; L.E.K. Consulting; Otsuka America Pharmaceutical, Inc.; Spring Care, Inc.; Sunovion Pharmaceuticals, Inc.; Takeda Industries; Taisho Pharmaceutical Co., Ltd.; Scientific Advisory Board; Bioasis Technologies, Inc.; Biohaven Pharmaceuticals; Blackthorn Therapeutics, Inc.; Broad Institute of MIT and Harvard; Cadent Therapeutics; Lohocla Research Corporation; Pfizer Pharmaceuticals; and Stanley Center for Psychiatric Research at the Broad Institute; (2) Stock: ArRETT Neuroscience, Inc.; Blackthorn Therapeutics, Inc.; Biohaven Pharmaceuticals Medical Sciences; and Spring Care, Inc. Stock options: Biohaven Pharmaceuticals Medical Sciences; (3) income greater than $10,000: Editorial Board.Editor - Biological Psychiatry; Patents and Inventions: Seibyl JP, Krystal JH, Charney DS. Dopamine and noradrenergic reuptake inhibitors in treatment of schizophrenia. US Patent #:5,447,948. September 5, 1995; Vladimir, Coric, Krystal, John H, Sanacora, Gerard – Glutamate Modulating Agents in the Treatment of Mental Disorders US Patent No. 8,778,979 B2 Patent Issue Date: July 15, 2014. US Patent Application No. 15/695,164:Filing date: September 5, 2017; Charney D, Krystal JH, Manji H, Matthew S, Zarate C., − Intranasal Administration of Ketamine to Treat Depression United States Application No. 14/197,767 filed on March 5, 2014; United States application or Patent Cooperation Treaty (PCT) International application No. 14/306,382 filed on June 17, 2014; Zarate, C, Charney, DS, Manji, HK, Mathew, Sanjay J, Krystal, JH, Department of Veterans Affairs “Methods for Treating Suicidal Ideation”, Patent Application No. 14/197.767 filed on March 5, 2014 by Yale University Office of Cooperative Research; Arias A, Petrakis I, Krystal JH. – Composition and methods to treat addiction; Provisional Use Patent Application no.61/973/961. April 2, 2014. Filed by Yale University Office of Cooperative Research; Chekroud, A., Gueorguieva, R., & Krystal, JH. “Treatment Selection for Major Depressive Disorder” [filing date June 3, 2016, USPTO docket number Y0087.70116US00]. Provisional patent submission by Yale University; Yoon G, Petrakis I, Krystal JH – Compounds, Compositions, and Methods for Treating or Preventing Depression and Other Diseases. US Provisional Patent Application No. 62/444,552, filed on.January 10, 2017, by Yale University Office of Cooperative Research OCR 7088 US01; Abdallah, C, Krystal, JH, Duman, R, Sanacora, G. Combination Therapy for Treating or Preventing Depression or Other Mood Diseases. U.S. Provisional Patent Application No. 047162-7177P1 (00754) filed on August 20, 2018, by Yale University Office of Cooperative Research OCR 7451 US01.All other authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.